Sensei Biotherapeutics (NASDAQ:SNSE) Trading 0.7% Higher – Here’s Why

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) traded up 0.7% on Monday . The company traded as high as $8.69 and last traded at $8.08. 4,928 shares were traded during trading, a decline of 77% from the average session volume of 21,807 shares. The stock had previously closed at $8.02.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Sensei Biotherapeutics in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $55.00.

Sensei Biotherapeutics Stock Up 0.7%

The business has a fifty day simple moving average of $8.11 and a two-hundred day simple moving average of $7.84. The company has a market capitalization of $10.18 million, a price-to-earnings ratio of -0.38 and a beta of 0.27.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($3.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.20) by $2.29. As a group, equities analysts predict that Sensei Biotherapeutics, Inc. will post -1.17 earnings per share for the current fiscal year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.